A novel non-invasive biomarker for assessment of small intestinal mucositis in children with cancer undergoing chemotherapy

Simple item page
dc.contributor.authorTooley, K.
dc.contributor.authorSaxon, B.
dc.contributor.authorWebster, J.
dc.contributor.authorZacharakis, B.
dc.contributor.authorMcNeil, Y.
dc.contributor.authorDavidson, G.
dc.contributor.authorButler, R.
dc.date.issued2006
dc.description.abstractBackground: Small intestinal mucositis is a common side-effect following high-dose chemotherapy, causing patients to experience pain and abdominal complications often leading to extended stays in hospital. A biomarker to detect these small intestinal changes does not exist in clinical practice. This study aimed to assess the non-invasive 13C-Sucrose breath test (SBT) to detect small intestinal damage associated with mucositis in pediatric cancer patients having chemotherapy. Patients and Methods: Small intestinal function was assessed in 15 pediatric cancer patients and 26 healthy children. Subjects were studied for small intestinal permeability (SIP; lactulose/rhamnose), digestive and absorptive capacity (SBT; sucrose), and oro-cecal transit time (OCTT; lactulose), by ingesting two sugar drinks containing the respective sugars. Combined tests were carried out at baseline, day1, day3-5 and day6-9, and in healthy individuals on two separate occasions. A total of 25 cycles of chemotherapy were assessed. Breath samples for the SBT were collected every 15min for 3 h (expressed as % cumulative dose at 90min (CD)), a 5 h urine collection for SIP and breath hydrogen determined every 30min for 3 h for OCTT. Results: Clinical mucositis occurred in seven of the 25 cycles of chemotherapy (28%). No significant difference was observed for SIP and OCTT. The SBT %CD at 90min was significantly lower in the mucositis group compared to the unaffected group and controls at baseline (p < 0.05). Patients who developed mucositis maintained a significantly lower %CD, for all test points (p < 0.05) compared to the unaffected patients. In patients who developed mucositis the SBT was below the reference range of the controls at all time points. Conclusion: The findings show for the first time that it is possible to non-invasively detect and monitor gut damage associated with chemotherapy-inducedmucositis in pediatric cancer patients.
dc.description.statementofresponsibilityTooley, Katie L ; Saxon, Ben R ; Webster, Judy ; Zacharakis, Betty ; McNeil, Yvette ; Davidson, Geoffrey P ; Butler, Ross N
dc.identifier.citationCancer Biology & Therapy, 2006; 5(10):1275-1281
dc.identifier.doi10.4161/cbt.5.10.3303
dc.identifier.issn1538-4047
dc.identifier.issn1555-8576
dc.identifier.orcidSaxon, B. [0000-0003-1598-5343]
dc.identifier.urihttp://hdl.handle.net/2440/35541
dc.language.isoen
dc.publisherLandes Bioscience
dc.source.urihttps://doi.org/10.4161/cbt.5.10.3303
dc.subjectIntestinal Mucosa
dc.subjectIntestine, Small
dc.subjectHumans
dc.subjectSucrose
dc.subjectAntineoplastic Agents
dc.subjectBreath Tests
dc.subjectPatient Selection
dc.subjectReference Values
dc.subjectAdolescent
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectFemale
dc.subjectMale
dc.subjectMucositis
dc.subjectBiomarkers
dc.titleA novel non-invasive biomarker for assessment of small intestinal mucositis in children with cancer undergoing chemotherapy
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Molecular and Biomedical Science publications